70
Participants
Start Date
December 31, 2013
Primary Completion Date
May 31, 2015
Study Completion Date
May 31, 2015
Intravitreal injection (bevacizumab or ranibizumab)
The intravitreal anti-vascular endothelial growth factor agent of 0.1 ml of bevacizumab (2.5 mg/0.1 ml) or ranibizumab (1 mg/0.1 ml)
Weerawat Kiddee, Hat Yai
Prince of Songkla University
OTHER